<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03685149</url>
  </required_header>
  <id_info>
    <org_study_id>HL143372-01</org_study_id>
    <nct_id>NCT03685149</nct_id>
  </id_info>
  <brief_title>Pilot Randomized Trial With Flecainide in ARVC Patients</brief_title>
  <official_title>Pilot Randomized Trial With Flecainide in ARVC Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wojciech Zareba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) is an inherited arrhythmia disorder
      with high risk of ventricular tachycardia or fibrillation, and implantable cardioverter
      defibrillator remains as therapy of choice. Antiarrhythmic therapy with different agents
      including beta-blockers, sotalol and amiodarone are usually not effective in reducing risk of
      arrhythmic events. Recent data indicated that flecainide effectively prevented the
      arrhythmias observed in the experimental ARVC animals and in small series of ARVC patients.
      These observations provide a strong rationale for conducting a pilot randomized clinical
      trial to determine whether flecainide will reduce ventricular arrhythmias in high-risk ARVC
      patients. This pilot study is designed as randomized double-blinded placebo-controlled
      crossover trial with administration of 100 mg of Flecainide or matching placebo twice a day
      for 4 weeks each with a washout period.

      Primary specific aim of this pilot trial is to determine whether Flecainide administration is
      associated with a significant reduction of number of ventricular ectopic beats (VEBs) in ARVC
      patients with implantable cardioverter-defibrillator (ICD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) is an inherited arrhythmia disorder
      with high risk of ventricular tachycardia or fibrillation, and implantable cardioverter
      defibrillator remains as therapy of choice. Antiarrhythmic therapy with different agents
      including beta-blockers, sotalol and amiodarone are usually not effective in reducing risk of
      arrhythmic events. Recent data indicated that flecainide effectively prevented the
      arrhythmias observed in the experimental ARVC animals and in small series of ARVC patients.
      These observations provide a strong rationale for conducting a pilot randomized clinical
      trial to determine whether flecainide will reduce ventricular arrhythmias in high-risk ARVC
      patients. This pilot study is designed as randomized double-blinded placebo-controlled
      crossover trial with administration of 100 mg of Flecainide or matching placebo twice a day
      for 4 weeks each with a washout period.

      Primary specific aim of this pilot trial is to determine whether Flecainide administration is
      associated with a significant reduction of number of ventricular ectopic beats (VEBs) in ARVC
      patients with implantable cardioverter-defibrillator (ICD).

      Secondary specific aims are:

        1. to assess safety of flecainide administration with particular emphasis on proarrhythmic
           response measured by:

             1. VPBs on ECG monitoring,

             2. nonsustained and sustained VT/VF episodes documented on ICD interrogation, and

             3. effects of Flecainide on QRS morphology and duration.

        2. to assess effects of flecainide on burden of VT runs in 7-day ECG recordings.

        3. to assess effects of flecainide on burden of atrial premature beats in 7-day recordings.

        4. to demonstrate feasibility of enrollment of rare inherited arrhythmia ARVC patients in a
           randomized study in the light of planned future large clinical trial with VT/VF/death as
           endpoint.

      Study population will include 38 ARVC patients diagnosed with the 2010 ARVC Task Force
      Criteria who are at least 18 years old, have implanted ICD, and show at least 500 VPBs in a
      24-hour Holter recording. Patients on other pharmacological antiarrhythmic treatment other
      than beta-blockers and patients with prior catheter VT ablation will be excluded.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 31, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a randomized double-blinded placebo-controlled crossover trial on the effect of flecainide on the frequency of ventricular arrhythmias of 38 ARVC patients. The crossover design requires a 10-week treatment with each patient receiving flecainide 100 mg bid and placebo for 4 weeks in a blinded randomized order.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>This is double-blinded trial with all participants, investigators, and outcome assessors being blinded with except for DSMB members.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of ventricular premature beats (VPBs)</measure>
    <time_frame>7-day period</time_frame>
    <description>Number of ventricular premature beats (VPBs) in a 7-day ECG recording</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proarrhythmic response to Flecainide</measure>
    <time_frame>7-day period</time_frame>
    <description>VPBs in 7-day ECG recording; nonsustained and sustained ventricular tachycardia and ventricular fibrillation recorded by implantable cardioverter-defibrillator during 4-week treatment periods; QRS morphology and duration in ECG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VT burden</measure>
    <time_frame>7-day period</time_frame>
    <description>Number of VT runs recorded on 7-day ECG recording</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of atrial premature beats (APBs)</measure>
    <time_frame>7-day period</time_frame>
    <description>Number of atrial premature beats (APBs) in a 7-day ECG recording</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of eligible to enrolled participants</measure>
    <time_frame>18-month period</time_frame>
    <description>Number of eligible subjects to enrolled subjects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Arrhythmogenic Right Ventricular Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Flecainide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The same subjects will be treated in a random order with flecainide or placebo for 4 weeks each with 1 week washout between crossover periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The same subjects will be treated in a random order with flecainide or placebo for 4 weeks each with 1 week washout between crossover periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flecainide Pill</intervention_name>
    <description>Flecainide pill or placebo 100 mg administered twice a day for 4 weeks each</description>
    <arm_group_label>Flecainide</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Tambocor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Flecainide pill or placebo 100 mg administered twice a day for 4 weeks each</description>
    <arm_group_label>Flecainide</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years.

          -  Subjects who have been diagnosed with ARVC and meet 2010 Modified Task Force Criteria
             for ARVC as affected.

          -  At minimum 500 VPBs on the most recent 24-hour Holter monitor recording prior to
             consent or after consent if a subsequent recording is required after 5 day washout
             following discontinuation of anti-arrhythmic medication.

          -  Functioning implanted cardioverter defibrillator with remote interrogation capability.

          -  Subjects should be on a beta-blocker including metoprolol, propranolol, atenolol,
             nadolol, carvedilol or bisoprolol unless contraindication to beta-blockers exists.

          -  Persons prescribed quinidine, procainamide, propafenone, disopyramide, dronedarone
             phenytoin, mexilitene, flecainide, may be included after 5 day washout period with
             subsequent 24 Hour Holter obtained after washout period.

          -  Persons prescribed sotalol must be included after 5 day washout period during which
             another beta-blocker may be administered with subsequent 24 Hour Holter obtained.

          -  Subject and personal physician and or cardiologist must agree not to use any
             antiarrhythmic medications during the 10 weeks of participation, unless needed for
             management of life-threatening arrhythmias.

          -  All subjects must agree to use medically acceptable contraceptive measures during
             participation unless documented as surgically sterile or post-menopausal (no menstrual
             periods for more than one year).

        Exclusion Criteria:

          -  Prescribed amiodarone or dofetilide at the time of consent.

          -  Left ventricular ejection fraction ≤40% by any imaging modality: echocardiography,
             angiography, CMRI, or cardiac nuclear test on the most recent test.

          -  NYHA heart failure class III or IV at time of consent.

          -  Prior myocardial infarction at any time in the past.

          -  Pacemaker dependent rhythm at the time of consent.

          -  Renal impairment (GFR &lt;30 mL/min/m2).

          -  Prior diagnosis of severe hepatic impairment.

          -  Pregnant or plan to become pregnant during the course of the trial (Flecainide has not
             been adequately studied in pregnant women). Pregnancy test is required for women of
             child-bearing potential prior to randomization.

          -  Participating in any other interventional clinical trial.

          -  Unwilling or unable to cooperate with the protocol.

          -  Lives at such a distance from the clinic that travel for the consent visit would be
             unusually difficult.

          -  Decisionally impaired adults, those of questionable capacity, those who cannot manage
             taking the study drug per the prescribed regimen, and those who cannot consent for
             themselves will not be recruited for this study.

          -  Unwilling to sign the consent for participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wojciech Zareba, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wojciech Zareba, MD, PhD</last_name>
    <phone>585-275-5391</phone>
    <email>wojciech_zareba@urmc.rochester.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katie Pyykkonen, MS</last_name>
    <phone>585-273-2244</phone>
    <email>Kathryn.Pyykkonen@heart.rochester.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Zipse, MD</last_name>
      <phone>720-848-6510</phone>
      <email>matthew.zpise@ucdenver.edu</email>
    </contact>
    <contact_backup>
      <last_name>Therese Jones, RN</last_name>
      <phone>7208486510</phone>
      <email>therese.l.jones@icdenver.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>John Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hugh Calkins, MD</last_name>
      <phone>410-502-7161</phone>
      <email>hcalkins@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Crystal Tichnell, MGC</last_name>
      <phone>4105027161</phone>
      <email>ctichne1@jhmi.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>New York University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Cerrone, MD</last_name>
      <phone>212-263-9163</phone>
      <email>marina.cerrone@nyulangone.org</email>
    </contact>
    <contact_backup>
      <last_name>Linda Borneman, RN</last_name>
      <phone>2122639163</phone>
      <email>linda.borneman@nyulangone.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Spencer Rosero, MD</last_name>
      <phone>585-275-4775</phone>
      <email>spencer_rosero@urmc.rochester.edu</email>
    </contact>
    <contact_backup>
      <last_name>Laura Wing</last_name>
      <phone>585-273-4128</phone>
      <email>laura_wing@urmc.rochester.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert Sun, MD</last_name>
      <phone>919-681-5816</phone>
      <email>albert.sun@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pensylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francis Marchlinski, MD</last_name>
      <phone>215-349-8446</phone>
      <email>francis.marchlinski@pennmedeicine.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mary Gnap, RN</last_name>
      <phone>2153498446</phone>
      <email>mary.gnap@pennmedicine.upenn.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Marcus FI, Zareba W, Calkins H, Towbin JA, Basso C, Bluemke DA, Estes NA 3rd, Picard MH, Sanborn D, Thiene G, Wichter T, Cannom D, Wilber DJ, Scheinman M, Duff H, Daubert J, Talajic M, Krahn A, Sweeney M, Garan H, Sakaguchi S, Lerman BB, Kerr C, Kron J, Steinberg JS, Sherrill D, Gear K, Brown M, Severski P, Polonsky S, McNitt S. Arrhythmogenic right ventricular cardiomyopathy/dysplasia clinical presentation and diagnostic evaluation: results from the North American Multidisciplinary Study. Heart Rhythm. 2009 Jul;6(7):984-92. doi: 10.1016/j.hrthm.2009.03.013. Epub 2009 Mar 11.</citation>
    <PMID>19560088</PMID>
  </reference>
  <reference>
    <citation>Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, Calkins H, Corrado D, Cox MG, Daubert JP, Fontaine G, Gear K, Hauer R, Nava A, Picard MH, Protonotarios N, Saffitz JE, Sanborn DM, Steinberg JS, Tandri H, Thiene G, Towbin JA, Tsatsopoulou A, Wichter T, Zareba W. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation. 2010 Apr 6;121(13):1533-41. doi: 10.1161/CIRCULATIONAHA.108.840827. Epub 2010 Feb 19.</citation>
    <PMID>20172911</PMID>
  </reference>
  <reference>
    <citation>Corrado D, Link MS, Calkins H. Arrhythmogenic Right Ventricular Cardiomyopathy. N Engl J Med. 2017 Jan 5;376(1):61-72. doi: 10.1056/NEJMra1509267. Review.</citation>
    <PMID>28052233</PMID>
  </reference>
  <reference>
    <citation>Cerrone M, Montnach J, Lin X, Zhao YT, Zhang M, Agullo-Pascual E, Leo-Macias A, Alvarado FJ, Dolgalev I, Karathanos TV, Malkani K, Van Opbergen CJM, van Bavel JJA, Yang HQ, Vasquez C, Tester D, Fowler S, Liang F, Rothenberg E, Heguy A, Morley GE, Coetzee WA, Trayanova NA, Ackerman MJ, van Veen TAB, Valdivia HH, Delmar M. Plakophilin-2 is required for transcription of genes that control calcium cycling and cardiac rhythm. Nat Commun. 2017 Jul 24;8(1):106. doi: 10.1038/s41467-017-00127-0.</citation>
    <PMID>28740174</PMID>
  </reference>
  <reference>
    <citation>Ermakov S, Gerstenfeld EP, Svetlichnaya Y, Scheinman MM. Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm. 2017 Apr;14(4):564-569. doi: 10.1016/j.hrthm.2016.12.010. Epub 2016 Dec 9.</citation>
    <PMID>27939893</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 21, 2018</study_first_submitted>
  <study_first_submitted_qc>September 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2018</study_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Wojciech Zareba</investigator_full_name>
    <investigator_title>Professor of Medicine/Cardiology</investigator_title>
  </responsible_party>
  <keyword>arrhythmogenic right ventricular cardiomyopathy</keyword>
  <keyword>ARVC</keyword>
  <keyword>Flecainide</keyword>
  <keyword>ventricualr arrhythmias</keyword>
  <keyword>implantable cardioverter-defibrillator</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Arrhythmogenic Right Ventricular Dysplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flecainide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>This is a small pilot trial with limited dataset which will be mostly explored by enrolling center investigators.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

